GlassScriptPhysician profile
James R Doran
NPI 1942249610
$633.65
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.39 · 2020: $19.42 · 2021: $574 · 2022: $23.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $155.92 | 2021 | |
| Novo Nordisk INC | $102.97 | 2021-2022 | |
| Pfizer INC. | $58.78 | 2021 | |
| Lilly USA, LLC | $54.10 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.40 | 2021 | |
| Janssen Pharmaceuticals, INC | $36.05 | 2021 | |
| Amarin Pharma, INC. | $35.77 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $28.39 | 2021 | |
| Scilex Pharmaceuticals INC. | $24.69 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $21.09 | 2021 | |
| Hologic Sales and Service, LLC | $19.42 | 2020 | |
| Sunovion Pharmaceuticals INC. | $17.39 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $15.34 | 2021 | |
| Merck Sharp & Dohme LLC | $11.34 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Doran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.